Back to all News & Events >
Our News
MIST (Mindfulness, Incontinence and Sexual function Treatment) Study Research Proposal for a Pilot Study
MIST (Mindfulness, Incontinence and Sexual function Treatment) Study Research Proposal for a Pilot Study Principal Investigators: Dr. Maryse Larouche/Dr. Geoffrey Cundiff Primary Contact: Nicole Koenig, Research Coordinator, 604-806-9829, nkoenig@providencehealth.bc.ca About the study: This study aims to determine if there is an impact on sexual distress using mindfulness-based sex therapy (MBST) in addition to standard urogynecologic care, in women […]
Mifepristone Implementation Research in Canada
Mifepristone implementation research in Canada – The CART-Mife Study Principal Investigator: Dr. Wendy Norman Primary Contact: Sarah Munro, Post-doctoral Fellow, 604-875-2424 ext 4990, Sarah.Munro@ubc.ca About the study: Mifepristone, approved by Health Canada, will be introduced in 2017. Currently 96% of Canadian abortions are surgical, largely concentrated in the largest cities close to the southern border. Overcoming […]
Canadian Sexual Health Survey Study
Canadian Sexual Health Survey Study Principal Investigators: Dr. Wendy Norman, Dr. Stirling Bryan Primary Contact: Eva McMillan, Research Coordinator, 604-875-2424 x 4871, eva.mcmillan@ubc.ca About the study: This study developed and validated the Canadian Sexual Health Survey (CSHS) that aimed to collect data on sexual and reproductive health among women aged 14-49 years throughout BC. The survey was then […]
Better Contraceptive Choices: Insertion timing and effectiveness of intrauterine and other contraceptive methods post-abortion
Better Contraceptive Choices: Insertion timing and effectiveness of intrauterine and other contraceptive methods post-abortion Principal Investigator: Dr. Wendy Norman Primary Contact: Weihong Chen, Research Coordinator, 604-875-2424 x 4894, Weihong.chen@ubc.ca About the study: This project includes two randomized controlled trials: 1) Immediate vs. delayed insertion of intrauterine contraception after second trimester abortion; and, 2) Is FlexiT non-inferior to […]
Attitudes and intentions to receive medical and surgical abortions among women seeking pregnancy termination
Principal Investigator: Dr. Brian Fitzsimmons Primary Contact: Nicole Prestley, Research Manager, 604-875-2424 ext 4956, Nicole.Prestley@cw.bc.ca About the study: Health Canada has recently approved Mifegymiso, a medication which is used around the world for medical termination of pregnancy. In order to understand how the use of this medication will impact Canadian women, WHRI is leading a study […]
WHRI Award Winners: UBC Department of OBGYN Academic Day
Congratulations to the WHRI’s Elizabeth McClymont and Dr. Chelsea Elwood for being awarded best Graduate Student and Best Fellow presentations at last Wednesday’s UBC Department of OBGYN Academic Day. Elizabeth McClymont, a Master’s student in Reproductive Sciences working with supervisor Dr. Deborah Money, received the Best Graduate Student award for her presentation, “Two-Year Efficacy of the […]
International Women’s Day Event #BeBoldForChange
Last Wednesday, March 8th, the Women’s Health Research Institute hosted an event to celebrate International Women’s Day. This free event was open to the public with presentations from a panel of experts in women’s health who shared the latest recommendations for a variety of health topics. Events such as these are crucial in empowering women […]
New WHRI Grant Facilitation Services
The WHRI is excited to announce that we have partnered with the Research and Technology Development Office (RTDO) at the BC Children’s Hospital Research Institute to now offer grant facilitation support to WHRI members. Our new grant facilitator, Amber Hui, has a Masters degree in Social and Personality Psychology from the City University of New […]
BC population-based study examines the link between diabetes medications and the risk of endometrial cancer
It is well recognized that women with type 2 diabetes have an increased risk of endometrial (uterine) cancer. There are various pharmacotherapy options for diabetes, including metformin and thiazolidinediones, which reduce insulin levels (insulin-sensitizing drugs), and secretagogues, which increase circulating insulin levels. As hyperinsulinemia is recognized as a risk factor for the development of endometrial […]